Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 236
Tipo Título / Nombre Autor(es) Año
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial Paiva B, Martínez Cuadrón D, Bergua Burgués J, Vives S, Lorenzo Algarra J, Tormo M, Martínez Sánchez P, Serrano J, Herrera P, Ramos F, Salamero O, LAvilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Merino J, Alfonso A, Prosper F, San Miguel J, Sanz MA, Montesinos P 2018
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments Ballesteros J, Martínez Cuadrón D, Martínez López J, Bergua Burgués J, Trmo M, Serrano J, González A, Pérez de Oteyza J, Vives S, Vidriales MB, Herrera P, Vera JA, López Martínez A, Fuente A de la, Amador Barcdiela L, Hernández Rivas JA, Fernández Fernández MA, Cervero C, Morillo D, Hernández P, Primo D, Gorrochategui J, Rojas JL, Troconiz I, Villoria J, Sanz M, Montesinos P 2018
Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, Diaz-Beyá M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez P, Amigo ML, Bergua JM, Calbacho M, Hernández-Rivas JM, Monsalvo S, Novo A, Cervera M, García-Guiñón A, Junca J, Ciudad J, Orfao A, Ribera JM 2018
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG) Bergua J, Martínez Cuadrón D, Boluda B, Martínez P, Rodríguez Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Carretero C, Jiménez Ubieto A, Prieto J, Díaz Beyá M, Brunet S, Benavente C, Pérez Simón JA, Suárez Varela S, Morcardó F, Sanz MA, Montesinos P 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM 2018
A subset of AML patients shows different quimiosensitivy ex vivo profiles to anthracyclines and its combination with cytarabine; could precision medicine be the key selection criterion? Martínez Cuadrón D, Ballesteros J, Martínez López J, Hernández P, Primo D, Gorrochategui J, Rojas JL, Bergua JM, Tormo M, Serrano J, González A, Pérez de Oteyza J, Vives S, Vidriales B, Herrera P, Vera JA, López A, Fuente A de la, Amador ML, Hernández Rivas JA, Fernández MA, Cerveró CJ, Morillo D, Megías JE, Sanz M, Montesinos P 2018
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E, PETHEMA Group, Spanish Society of Hematology 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P, CETLAM and PETHEMA groups 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P, CETLAM and PETHEMA groups 2018